The outbreak of the coronavirus disease 2019 (COVID-19), caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global …

Background Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the
replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of …

Post-acute sequelae of COVID-19 (PASC) is emerging as global problem with unknown
molecular drivers. Using a digital epidemiology approach, we recruited 8,077 individuals to …

Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as a potential therapy for …

Background No effective pharmacological or non-pharmacological interventions exist for
patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for …

Background Mortality rates are high among hospitalized patients with COVID-19, especially
in those intubated on the ICU. Insight in pathways associated with unfavourable outcome …

Background Vitamin D deficiency has been suggested to favor a poorer outcome of
Coronavirus disease-19 (COVID-19). We aimed to assess if 25-hydroxyvitamin-D (25OHD) …

Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

COVID‐19 is a complex disease manifesting in a broad severity spectrum and involving
distinct organs and systems. Hyperinflammation, including complement over‐activation, has …

Advances in understanding the physiologic functions of the tumor necrosis factor
superfamily (TNFSF) of ligands, receptors, and signaling networks are providing deeper …